AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8543705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention treatment
Number of subjects: 212
Study 8543705 — intervention group
Group type: COMPARATOR
Intervention: Nonbehavioral treatment
Number of subjects: 212
Study 8543705 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skill training
Number of subjects: 212
Study 8543705 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy for avoiding marijuana use
Number of subjects: 212
Study 2196038 — intervention group
Group type: EXPERIMENTAL
Intervention: Translucent occluder
Number of subjects: 10
Study 2196038 — intervention group
Group type: COMPARATOR
Intervention: Opaque occluder
Number of subjects: 10
Study 7437240 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (D)
Number of subjects: 7
Study 7437240 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine (L)
Number of subjects: 7
Study 31756547 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 115
Study 31756547 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy
Number of subjects: 115
Study 31810194 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative Dietary Protocol (QDP; 'Diet4Hashi') applied in the experimental group.
Number of subjects: 100
Study 31810194 — intervention group
Group type: COMPARATOR
Intervention: Conventional Dietetic Counseling (CDC) applied in the control group.
Number of subjects: 100
Study 28164463 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop gastric electrical stimulation (CLGES) system
Number of subjects: 45
Study 25556611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 100-800 μg
Number of subjects: 330
Study 25556611 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase (FBT)
Number of subjects: 330
Study 23499228 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic alignment changes (angular: 3° and 6° of flexion, extension, abduction, adduction; translational: 5mm and 10mm of anterior, posterior, medial, lateral)
Number of subjects: 11
Study 21829747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (10 mg/kg/day for 3 days)
Number of subjects: 494
Study 21829747 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (30 mg/kg/day for 3 days in two divided doses)
Number of subjects: 494
Study 21829747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 494
Study 19951337 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute inpatient orthopaedic‐geriatric care
Number of subjects: 0
Study 19951337 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacute rehabilitation
Number of subjects: 0
Study 19951337 — intervention group
Group type: EXPERIMENTAL
Intervention: Community‐based rehabilitation
Number of subjects: 0
Study 19951337 — intervention group
Group type: COMPARATOR
Intervention: Various orthopaedic‐geriatric models of care
Number of subjects: 0
Study 17378192 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Houxi (SI 3), treated once daily for 3 sessions (1 course)
Number of subjects: 300
Study 17378192 — intervention group
Group type: COMPARATOR
Intervention: Medication group with Mobike, 7.5 mg once daily
Number of subjects: 300
Study 17010857 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of lens epithelial cells (LECs) from under the anterior capsule
Number of subjects: 100
Study 17010857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspiration of LECs)
Number of subjects: 100
Study 14647218 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast followed by lunch (same mixed macronutrient meal)
Number of subjects: 2
Study 14647218 — intervention group
Group type: COMPARATOR
Intervention: Lunch only (no breakfast)
Number of subjects: 2
Study 10522582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diltiazem (0.2 mg x kg(‐1)) and lidocaine (1.0 mg x kg(‐1))
Number of subjects: 60
Study 10522582 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (0.2 mg x kg(‐1))
Number of subjects: 60
Study 10522582 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.0 mg x kg(‐1))
Number of subjects: 60
Study 8542008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg to a maximum of 60 mg)
Number of subjects: 86
Study 1931867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin tertile 1
Number of subjects: 83
Study 1931867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin tertile 2
Number of subjects: 83
Study 1931867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma insulin tertile 3
Number of subjects: 83
Study 1931867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin concentration
Number of subjects: 83
Study 7046104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid (A-CA) 250 mg/125 mg, taken 3 times daily for 7 days
Number of subjects: 164
Study 7046104 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin 250 mg capsules, taken 3 times daily for 7 days
Number of subjects: 164
Study 7046104 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid (A-CA) after treatment failure on amoxycillin
Number of subjects: 164
Study 31218863 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-pressed ceramic RBFPDs, no cyclic loading (E0)
Number of subjects: 64
Study 31218863 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic RBFPDs, no cyclic loading (W0)
Number of subjects: 64
Study 31218863 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-pressed ceramic RBFPDs exposed to 300,000 cycles of dynamic loading (E1)
Number of subjects: 64
Study 31218863 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia ceramic RBFPDs exposed to 300,000 cycles of dynamic loading (W1)
Number of subjects: 64
Study 31218863 — intervention group
Group type: COMPARATOR
Intervention: Maximum bite force in the premolar region
Number of subjects: 64
Study 31218863 — intervention group
Group type: COMPARATOR
Intervention: Comparison between W0 and E0
Number of subjects: 64
Study 31218863 — intervention group
Group type: COMPARATOR
Intervention: Comparison between E1 and W1
Number of subjects: 64
Study 31218863 — intervention group
Group type: COMPARATOR
Intervention: Comparison between W0 and W1
Number of subjects: 64
Study 31218863 — intervention group
Group type: COMPARATOR
Intervention: Comparison between E0 and E1
Number of subjects: 64
Study 28161079 — intervention group
Group type: EXPERIMENTAL
Intervention: Active RFc therapy (90 J/cm2)
Number of subjects: 0
Study 28161079 — intervention group
Group type: COMPARATOR
Intervention: Sham RFc therapy (1 J/cm2)
Number of subjects: 0
Study 25599275 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 g fish and mussels/week for 26 weeks (50 μg selenium/day)
Number of subjects: 102
Study 25599275 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 102
Study 23873558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial 6-phytase (500, 1,000, or 2,000 phytase units/kg) with tricalcium phosphate (experiment 1)
Number of subjects: 496
Study 23873558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial 6-phytase (500 or 1,000 phytase units/kg) with monocalcium phosphate (experiment 2)
Number of subjects: 496
Study 23873558 — intervention group
Group type: COMPARATOR
Intervention: Negative control diet (NC)
Number of subjects: 496
Study 23873558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial 6-phytase
Number of subjects: 496
Study 21110034 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-selected music (classical, relaxing modern, smooth jazz)
Number of subjects: 200
Study 21110034 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized music therapy (classical, relaxing modern, smooth jazz)
Number of subjects: 200
Study 21110034 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 200
Study 19819121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target HbA(1c) <7.0%)
Number of subjects: 8
Study 19819121 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target HbA(1c) 7.0‐7.9%)
Number of subjects: 8
Study 19819121 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 8
Study 16798785 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment (TAC-O)
Number of subjects: 121
Study 16798785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone acetate (HA) and 0.1% hydrocortisone butyrate ointment (HC-O)
Number of subjects: 121
Study 16798785 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-atopic dermatitis children)
Number of subjects: 121
Study 15482582 — intervention group
Group type: EXPERIMENTAL
Intervention: si‐jue‐shi‐diao (dys‐regulation of thought and perception)
Number of subjects: 313
Study 15482582 — intervention group
Group type: EXPERIMENTAL
Intervention: jing‐shen‐fen‐lie‐zheng (mind‐split-disease)
Number of subjects: 313
Study 15482582 — intervention group
Group type: EXPERIMENTAL
Intervention: jing‐shen‐bin (mental illness)
Number of subjects: 313
Study 15482582 — intervention group
Group type: COMPARATOR
Intervention: no label
Number of subjects: 313
Study 11819709 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion with herbal medicine
Number of subjects: 46
Study 11819709 — intervention group
Group type: COMPARATOR
Intervention: Salicylaye fapyridine (SASP)
Number of subjects: 46
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group B
Number of subjects: 6334
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rh D negative
Number of subjects: 6334
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: M gene
Number of subjects: 6334
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: M s haplotype
Number of subjects: 6334
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: S gene
Number of subjects: 6334
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: Duffy group alleles Fy (a‐b‐)
Number of subjects: 6334
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ss group alleles S‐ s‐
Number of subjects: 6334
Study 9378531 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidd blood group system alleles JK (a‐b‐)
Number of subjects: 6334
Study 8473676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination TAO and methylprednisolone (MPn)
Number of subjects: 18
Study 8473676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination TAO and prednisone
Number of subjects: 18
Study 8473676 — intervention group
Group type: COMPARATOR
Intervention: MPn alone
Number of subjects: 18
Study 3936866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoglobulin (12 g as a 3% solution on day 0, day 5, and day 12, total of 36 g)
Number of subjects: 150
Study 3936866 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 150
Study 3936866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoglobulin (IGIV)
Number of subjects: 150
Study 28674819 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-bow registration for remounting complete dentures
Number of subjects: 32
Study 28674819 — intervention group
Group type: COMPARATOR
Intervention: Mean setting for remounting complete dentures
Number of subjects: 32
Study 27292543 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed bright light therapy
Number of subjects: 144
Study 27292543 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime melatonin supplementation
Number of subjects: 144
Study 27292543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both timed bright light therapy and bedtime melatonin
Number of subjects: 144
Study 27292543 — intervention group
Group type: COMPARATOR
Intervention: Placebos only
Number of subjects: 144
Study 24157445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber mixture
Number of subjects: 54
Study 24157445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 54
Study 23135172 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ART (cART)
Number of subjects: 101
Study 23135172 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Treatment Interruption (PTI)
Number of subjects: 101
Study 21039348 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg) twice per day
Number of subjects: 212
Study 19122486 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast feeding promotion program for working women
Number of subjects: 0
Study 16372264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from patients with acute K. pneumoniae infections
Number of subjects: 70
Study 16372264 — intervention group
Group type: COMPARATOR
Intervention: Sera from healthy individuals (control group)
Number of subjects: 70
Study 16372264 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunogenic proteins identified
Number of subjects: 70
Study 16372264 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine candidate genes OmpA and FepA
Number of subjects: 70
Study 14585250 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive Lifestyle Management Intervention (ELMI)
Number of subjects: 302
Study 14585250 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study 15200045 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Number of subjects: 30
Study 15200045 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 10689628 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 21
Study 10689628 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate
Number of subjects: 21
Study 8941832 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ionic toothbrush
Number of subjects: 64
Study 8941832 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 64
Study 1773691 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 47
Study 1773691 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 47
Study 1773691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Verapamil and Enalapril
Number of subjects: 47
Study 6415987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6415987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide from day 1 to 6
Number of subjects: 23
Study 6415987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment from day 1 to 3
Number of subjects: 23
Study 30368651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer education strategy led by community health volunteers (CHVs)
Number of subjects: 525
Study 31529295 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (200 μgr daily for 1 year)
Number of subjects: 102
Study 31529295 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 102
Study 28800147 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 107
Study 28800147 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (control)
Number of subjects: 107
Study 26572093 — intervention group
Group type: EXPERIMENTAL
Intervention: F5K TV reduction program
Number of subjects: 160
Study 26572093 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual Head Start curriculum)
Number of subjects: 160
Study 24560477 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal misoprostol (400 mcg)
Number of subjects: 196
Study 24560477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 22412143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice a day with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Number of subjects: 229
Study 22412143 — intervention group
Group type: COMPARATOR
Intervention: Placebo with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Number of subjects: 229
Study 22412143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg orally twice a day
Number of subjects: 229
Study 22412143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 18973893 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 100 mg aspirin
Number of subjects: 169
Study 18973893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 17685695 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 13
Study 17685695 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training
Number of subjects: 13
Study 16234523 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (vincristine, cisplatin, cyclophosphamide, and etoposide)
Number of subjects: 299
Study 16234523 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy (vincristine, carboplatin, ifosfamide, and etoposide)
Number of subjects: 299
Study 16234523 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (both regimens)
Number of subjects: 299
Study 11994333 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt diet plus potassium citrate (90 mmol/d)
Number of subjects: 60
Study 11994333 — intervention group
Group type: COMPARATOR
Intervention: High-salt diet plus placebo
Number of subjects: 60
Study 9850205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 47
Study 9850205 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 7523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (5 mg 4 times daily)
Number of subjects: 51
Study 7523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg 3 times daily)
Number of subjects: 51
Study 7523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (280 mg 2-3 times daily)
Number of subjects: 51
Study 7523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m2 i.v. every 3rd week)
Number of subjects: 51
Study 7523131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (all drugs)
Number of subjects: 51
Study 2790689 — intervention group
Group type: EXPERIMENTAL
Intervention: Double lumen central venous catheter
Number of subjects: 43
Study 2790689 — intervention group
Group type: COMPARATOR
Intervention: Totally implantable venous access system
Number of subjects: 43
Study 61389 — intervention group
Group type: EXPERIMENTAL
Intervention: Methandienone (100 mg/day for 6 weeks)
Number of subjects: 11
Study 61389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 61389 — intervention group
Group type: EXPERIMENTAL
Intervention: Methandienone
Number of subjects: 11
Study 30911659 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC with doxorubicin and cisplatin (1 PIPAC then 2 IV Chemo)
Number of subjects: 94
Study 30911659 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy only
Number of subjects: 94
Study 27639130 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2mA, anode: dorsolateral prefrontal cortex, cathode: orbitofrontal cortex)
Number of subjects: 29
Study 27639130 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation (sham stimulation)
Number of subjects: 29
Study 27639130 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 29
Study 27639130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure
Number of subjects: 29
Study 25772701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg preoperatively and 200 mg postoperatively on the day of surgery, continued at 200 mg three times daily for two days.
Number of subjects: 102
Study 25772701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 25772701 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 102
Study 23687259 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 250
Study 23687259 — intervention group
Group type: COMPARATOR
Intervention: INX
Number of subjects: 250
Study 20673347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictogram format
Number of subjects: 800
Study 20673347 — intervention group
Group type: EXPERIMENTAL
Intervention: Metonym format
Number of subjects: 800
Study 20673347 — intervention group
Group type: COMPARATOR
Intervention: Bar graph format with pre-intervention questionnaire
Number of subjects: 800
Study 20673347 — intervention group
Group type: COMPARATOR
Intervention: Bar graph format without pre-intervention questionnaire
Number of subjects: 800
Study 18194800 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum dexamethasone
Number of subjects: 105
Study 18194800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 16372163 — intervention group
Group type: EXPERIMENTAL
Intervention: MSR patients
Number of subjects: 10
Study 16372163 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 10
Study 14566252 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol)
Number of subjects: 70
Study 14566252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 11168342 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid supplementation (2.08 g for 21 days)
Number of subjects: 29
Study 11168342 — intervention group
Group type: COMPARATOR
Intervention: Control group (without diabetes)
Number of subjects: 29
Study 9294377 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine treatment for 15 months
Number of subjects: 62
Study 9294377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9294377 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine treatment
Number of subjects: 62
Study 8334085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 1292
Study 8334085 — intervention group
Group type: COMPARATOR
Intervention: Control group (withholding cervical cerclage)
Number of subjects: 1292
Study 3635546 — intervention group
Group type: EXPERIMENTAL
Intervention: Information group (received information as part of the research interview)
Number of subjects: 0
Study 3635546 — intervention group
Group type: COMPARATOR
Intervention: Control group (received no information)
Number of subjects: 0